Bowel Movement Frequency Is Not Linked With Cognitive Function in Cirrhosis
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved..
The spectrum of hepatic encephalopathy (HE) ranges from overt HE (OHE) to cognitive impairment (ie, covert) HE (CHE).1 The first-line therapy is lactulose, which is titrated to achieve ~2-3 soft/loose daily bowel movements (BM). This metric is considered dogma for practitioners despite erratic results, GI adverse events, and poor tolerance in Western countries.1 There are logistic barriers for the widespread uptake of rifaximin, the second-line therapy. Moreover, although BM frequency-directed dose titration of lactulose is the usual practice, its impact on objective cognitive performance is unclear. Our aim is to determine the impact of BM frequency on cognition in patients with/without prior OHE.
| Errataetall: |
CommentIn: Clin Gastroenterol Hepatol. 2022 May;20(5):e1220-e1221. - PMID 34058412 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 20(2022), 4 vom: 15. Apr., Seite e897-e901 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duong, Nikki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4618-18-2 |
|---|
| Anmerkungen: |
Date Completed 16.03.2022 Date Revised 02.04.2023 published: Print-Electronic CommentIn: Clin Gastroenterol Hepatol. 2022 May;20(5):e1220-e1221. - PMID 34058412 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cgh.2021.05.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325429987 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325429987 | ||
| 003 | DE-627 | ||
| 005 | 20231225192424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2021.05.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325429987 | ||
| 035 | |a (NLM)33991690 | ||
| 035 | |a (PII)S1542-3565(21)00517-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duong, Nikki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bowel Movement Frequency Is Not Linked With Cognitive Function in Cirrhosis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.03.2022 | ||
| 500 | |a Date Revised 02.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Gastroenterol Hepatol. 2022 May;20(5):e1220-e1221. - PMID 34058412 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The spectrum of hepatic encephalopathy (HE) ranges from overt HE (OHE) to cognitive impairment (ie, covert) HE (CHE).1 The first-line therapy is lactulose, which is titrated to achieve ~2-3 soft/loose daily bowel movements (BM). This metric is considered dogma for practitioners despite erratic results, GI adverse events, and poor tolerance in Western countries.1 There are logistic barriers for the widespread uptake of rifaximin, the second-line therapy. Moreover, although BM frequency-directed dose titration of lactulose is the usual practice, its impact on objective cognitive performance is unclear. Our aim is to determine the impact of BM frequency on cognition in patients with/without prior OHE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 7 | |a Lactulose |2 NLM | |
| 650 | 7 | |a 4618-18-2 |2 NLM | |
| 650 | 7 | |a Rifaximin |2 NLM | |
| 650 | 7 | |a L36O5T016N |2 NLM | |
| 700 | 1 | |a Reuter, Bradley |e verfasserin |4 aut | |
| 700 | 1 | |a Saraireh, Hamzeh |e verfasserin |4 aut | |
| 700 | 1 | |a Nadhem, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Acharya, Chathur |e verfasserin |4 aut | |
| 700 | 1 | |a Fagan, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Hassouneh, Ramzi |e verfasserin |4 aut | |
| 700 | 1 | |a Bajaj, Jasmohan S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g 20(2022), 4 vom: 15. Apr., Seite e897-e901 |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:4 |g day:15 |g month:04 |g pages:e897-e901 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2021.05.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 4 |b 15 |c 04 |h e897-e901 | ||